Moreover, we identify CDK7/12/13 inhibitors as novel compound class that targets diverse routes in this network and synergizes with the Bcl‐2 inhibitor venetoclax to eradicate primary human AML cells. The gene discussed is BCL2; the disease is acute myeloid leukemia.